H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $85.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Trucchio has given his Buy rating due to a combination of factors, primarily focusing on the promising potential of Arrowhead Pharmaceuticals’ obesity treatments. The recent interim data from Wave Life Sciences on WVE-007, which targets the INHBE gene, has strengthened confidence in Arrowhead’s similar approach with ARO-INHBE. The data demonstrated significant reductions in visceral fat and total fat mass, validating INHBE as a therapeutic target for obesity and supporting the biological rationale for Arrowhead’s program.
Arrowhead’s innovative TRiM platform, which has shown deep and long-lasting effects in hepatic targets, is expected to achieve similar success in obesity treatments. The company’s two candidates, ARO-INHBE and ARO-ALK7, are progressing through early clinical development, with initial data anticipated in early January 2026. These candidates target genetically validated mechanisms associated with reduced visceral fat and improved metabolic health, positioning them as leading RNA interference-based programs in obesity. Ahead of these clinical readouts, Trucchio reiterates a Buy rating and sets a price target of $85 for Arrowhead Pharmaceuticals.
Trucchio covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Aligos Therapeutics, and Altimmune. According to TipRanks, Trucchio has an average return of 35.0% and a 56.24% success rate on recommended stocks.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $81.00 price target.